Analysis

  • 9 October 2018

    September’s top news stories

    Emerald Health Pharmaceuticals (EHP) started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma, and Ra Pharmaceuticals reported...

  • 17 September 2018

    The 7 Deadly Sins of Audits and Inspections

    Stuart Halasz, Associate Director, Clinical Quality Management, Merck & Co., Inc., focuses on “7 Deadly Sins” in Audits and Inspections – and thoughts on reducing their occurrence

  • 31 August 2018

    August’s top news stories

    Gradalis started a Phase lll clinical trial of Vigil in combination with irinotecan and temozolomide for the treatment of patients with Ewing’s sarcoma, and Impel NeuroPharma dosed the first subject...

Close
Close
Close

Go Top